| Name | Title | Contact Details |
|---|
Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.
Remedi SeniorCare is a United States-based institutional pharmacy business, serving a growing number of facilities extending from the Mid-Atlantic to the Midwest.
ValueOptions Inc., the nation's largest independent behavioral health care and wellness company, specializes in management for all behavioral health issues, and mental health and chemical dependency diagnoses.
Bryn Pharma is a privately held pharmaceutical company based in North Carolina. Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis.
Watson Laboratories is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.